Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial).
about
The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemiaTriglyceride-rich lipoproteins as a causal factor for cardiovascular diseaseNutraceuticals and Bioactive Components from Fish for Dyslipidemia and Cardiovascular Risk ReductionPrescription omega-3 fatty acid products: considerations for patients with diabetes mellitusOrigin and therapy for hypertriglyceridaemia in type 2 diabetesOverview of prescription omega-3 fatty acid products for hypertriglyceridemiaA Comparative Overview of Prescription Omega-3 Fatty Acid ProductsRationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial.Effect of icosapent ethyl (eicosapentaenoic acid ethyl ester) on omeprazole plasma pharmacokinetics in healthy adults.Efficacy of a unique omega-3 formulation on the correction of nutritional deficiency and its effects on cardiovascular disease risk factors in a randomized controlled VASCAZEN(®) REVEAL Trial.Current evidence for the clinical use of long-chain polyunsaturated n-3 fatty acids to prevent age-related cognitive decline and Alzheimer's disease.The use of dietary supplements to alleviate androgen deprivation therapy side effects during prostate cancer treatmentPhase 1 study of the effect of icosapent ethyl on warfarin pharmacokinetic and anticoagulation parameters.Effect of concomitant icosapent ethyl (eicosapentaenoic acid ethyl ester) on the pharmacokinetics of atorvastatin.Lowering triglycerides to modify cardiovascular risk: will icosapent deliver?Update on the management of severe hypertriglyceridemia--focus on free fatty acid forms of omega-3.Pharmacokinetics of Eicosapentaenoic Acid in Plasma and Red Blood Cells After Multiple Oral Dosing With Icosapent Ethyl in Healthy Subjects.Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Pharmacokinetic Parameters of Rosiglitazone in Healthy Subjects.Retrospective Case Series of Patients with Diabetes or Prediabetes Who Were Switched from Omega-3-Acid Ethyl Esters to Icosapent EthylPROMETHEUS: an observational, cross-sectional, retrospective study of hypertriglyceridemia in Russia.Dose-response effects of marine omega-3 fatty acids on apolipoproteins, apolipoprotein-defined lipoprotein subclasses, and Lp-PLA2 in individuals with moderate hypertriglyceridemia.Omega-3 fatty acid supplementation and cardiovascular disease.Titrating lovaza from 4 to 8 to 12 grams/day in patients with primary hypertriglyceridemia who had triglyceride levels >500 mg/dl despite conventional triglyceride lowering therapyIcosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies.Switching statin-treated patients from fenofibrate to the prescription omega-3 therapy icosapent ethyl: a retrospective case series.Eicosapentaenoic Acid Inhibits Oxidation of ApoB-containing Lipoprotein Particles of Different Size In Vitro When Administered Alone or in Combination With Atorvastatin Active Metabolite Compared With Other Triglyceride-lowering Agents.Omega-3 Fatty Acid Formulations in Cardiovascular Disease: Dietary Supplements are Not Substitutes for Prescription Products.Switching from EPA + DHA (Omega-3-acid Ethyl Esters) to High-Purity EPA (Icosapent Ethyl) in a Statin-Treated Patient with Persistent Dyslipidemia and High Cardiovascular Risk: A Case Study.Polyunsaturated fatty acyl-coenzyme As are inhibitors of cholesterol biosynthesis in zebrafish and mice.Established and emerging approaches for the management of dyslipidaemia.Overview of omega-3 Fatty Acid therapiesPrescription omega-3 fatty acid products containing highly purified eicosapentaenoic acid (EPA)Reduced Glycemic Variability in Diazoxide-Responsive Children with Congenital Hyperinsulinism Using Supplemental Omega-3-Polyunsaturated Fatty Acids; A Pilot Trial with MaxEPA(R.).DHA derivatives of fish oil as dietary supplements: a nutrition-based drug discovery approach for therapies to prevent metabolic cardiotoxicity.A Review of Clinical Practice Guidelines for the Management of Hypertriglyceridemia: A Focus on High Dose Omega-3 Fatty Acids.Is combination therapy an effective way of reaching lipid goals in type 2 diabetes mellitus?New lipid-lowering drugs: an update.U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma.Epanova(®) and hypertriglyceridemia: pharmacological mechanisms and clinical efficacy.Icosapent ethyl for the treatment of hypertriglyceridemia.
P2860
Q26738554-5A54E16C-B685-4423-BCA9-83057D7C2674Q26745946-F432F0B1-BDE3-4F91-8569-8D121251D130Q26747475-BA926428-C41E-4A0A-88C5-54024DFAAA45Q26752919-0D660CD1-7BB7-46A0-A421-E3F763B3A361Q26824004-4F1A5EC7-A79E-4B6D-B6CB-C95E5279CC3BQ28251391-BC2C3C9D-A936-4F1F-850F-565546748BF7Q28972330-D135467A-A057-4FE0-9CF4-31A5C82F277BQ33578422-E097C370-1285-4ECA-A676-70DFFC0873F7Q34130383-CABDE311-0CEC-4C31-8D89-D57450186A9BQ34250605-734AB325-0935-4ADC-8264-41D012999E0AQ34330929-6D87DC62-94FA-4365-857A-25BC68D23F86Q34411758-E0180EBE-8681-432A-A66F-EFC0A3B8FBCEQ34416861-218EC003-C849-464B-9503-43798E79C0CEQ34451932-AE0CACE9-B7E1-4C5A-9500-B8CCD91AA4B6Q35230819-51308BD5-FFA4-4E51-9B4A-4209255D5A19Q35460381-38622754-4F00-4AAD-A8E7-3F6AD13E9E9BQ35741991-533F45CB-DCC2-4418-B22C-F0773F360350Q35742023-BF4DA489-AE5C-413B-AE79-A2FED2E00889Q35756633-10C7F125-2B56-46B6-BD32-154EA7A6627CQ35995033-9A92012D-7715-4503-8B41-A1F2502B3D62Q36368459-3FDDCFCB-6C9C-4658-BBCE-6D5B3D41B03CQ36387184-A2EC9013-56FD-4FE8-A128-0E98A6D2F84AQ36552201-BD902517-0CDD-46A2-8A62-728CC1490E03Q36609778-C4873F88-148A-4CB9-8FCA-644CD4E355CBQ36712679-B601DE2D-027E-4A5A-809E-09E9B8D0D02BQ37074239-1EF35335-16A5-4BB3-BE1D-7A0FD8B115DFQ37099337-617E5FC5-AE4B-4E21-BA33-6A5741756308Q37118744-89905CB2-F230-43A7-9888-558166FB8BCEQ37287426-9F3F773A-E7EA-43FA-BC59-3F006DAD88D8Q37288105-124984EA-433F-4E5E-A043-8AFAE76E65E6Q37419411-B590D5D2-DC4F-413F-AE4B-CB8050803E83Q37615904-3F9E5CA0-0E5C-428B-A1EB-0F3516504ED1Q37634286-7853305A-03F2-4962-B2B5-A6840BAAF0ACQ37671776-0B79F180-B5C4-4E46-AC7F-8B1C4919BC48Q37672465-D1FCB34B-DC34-4FC9-A9F6-027C5A651A9FQ37964753-41D23416-77CD-4EE3-9B67-96C39A18B4B7Q37984782-DF1CDBA3-CF16-462E-9B4E-917E39722379Q38042090-1713BF46-4688-47DE-A73C-91F660225EE3Q38086841-DBBA5B5E-D16F-4942-9151-67297451DD7CQ38108834-8FA8DC5D-959E-49F3-8D89-D138E0B1FCA3
P2860
Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial).
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Eicosapentaenoic acid ethyl es ...... bel Extension [MARINE] trial).
@ast
Eicosapentaenoic acid ethyl es ...... bel Extension [MARINE] trial).
@en
Eicosapentaenoic acid ethyl es ...... bel Extension [MARINE] trial).
@nl
type
label
Eicosapentaenoic acid ethyl es ...... bel Extension [MARINE] trial).
@ast
Eicosapentaenoic acid ethyl es ...... bel Extension [MARINE] trial).
@en
Eicosapentaenoic acid ethyl es ...... bel Extension [MARINE] trial).
@nl
prefLabel
Eicosapentaenoic acid ethyl es ...... bel Extension [MARINE] trial).
@ast
Eicosapentaenoic acid ethyl es ...... bel Extension [MARINE] trial).
@en
Eicosapentaenoic acid ethyl es ...... bel Extension [MARINE] trial).
@nl
P2093
P921
P1476
Eicosapentaenoic acid ethyl es ...... bel Extension [MARINE] trial).
@en
P2093
Christie M Ballantyne
Harold E Bays
John J Kastelein
Jonathan L Isaacsohn
Paresh N Soni
Rene A Braeckman
P304
P356
10.1016/J.AMJCARD.2011.04.015
P407
P577
2011-06-16T00:00:00Z